Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

Log in / Sign up

Please sign in to follow a disease.

← Back to home

Neurimmune AG

Clinical trials sponsored by Neurimmune AG, explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

Second dose of experimental drug may help heart amyloidosis patients Results expected Oct 2026 (estimated)

Browse trials soon ready across all sponsors →

Not yet finished but already full! 1

Second dose of experimental drug may help heart amyloidosis patients

Disease control Ongoing

This study tests whether a second round of treatment with ALXN2220 is safe and can improve heart function in people with transthyretin amyloid cardiomyopathy, a condition where abnormal proteins build up in the heart. About 35 adults who previously received the drug will get it a…

Phase 2 • Sponsor: Neurimmune AG • Aim: Disease control

Last updated Jun 27, 2026 08:05 UTC